Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie announced top-line results from the Phase 3b Heads Up study, demonstrating that upadacitinib (30 mg, once daily) achieved superior results to dupilumab (300 mg, every other week) in treating moderate to severe atopic dermatitis. At week 16, 71% of patients on upadacitinib reached EASI 75 compared to 61% on dupilumab (p=0.006). Upadacitinib also outperformed in itch reduction and skin clearance, with significant improvements seen as early as week 1. The safety profile was consistent with previous studies, though a treatment-related death was reported. Further results will be submitted for publication.
AbbVie announced positive results from the Phase 3 U-ACHIEVE study, demonstrating that upadacitinib (45 mg daily) achieved clinical remission in 26% of patients with moderate to severe ulcerative colitis at week 8, significantly outperforming the 5% in the placebo group (p<0.001). The study also reported enhanced endoscopic and histologic improvement rates of 36% and 30%, respectively, compared to placebo. Upadacitinib's safety profile remained consistent with prior studies, showing a low incidence of serious adverse events. Future results will be presented at medical meetings.
AbbVie announced promising results from an integrated analysis of two Phase 3 studies regarding the use of IMBRUVICA in treating high-risk chronic lymphocytic leukemia (CLL) patients. The long-term follow-up showed similar progression-free survival (PFS) and overall response rates (ORR) in high-risk and non-high-risk patients. With data spanning up to 8 years, the study demonstrated sustained efficacy of IMBRUVICA, significantly improving outcomes for patients with known poor prognostic markers. These findings underscore the importance of appropriate biomarker testing in optimizing treatment strategies for CLL patients.
AbbVie (NYSE: ABBV) presented new Phase 3 MURANO and CLL14 trial results at the 62nd ASH Annual Meeting, emphasizing the effectiveness of VENCLEXTA/VENCLYXTO in chronic lymphocytic leukemia (CLL). The MURANO trial showed a median progression-free survival (PFS) of 53.6 months with VenR versus 17.0 months with BR. The overall survival (OS) estimate was 82.1% for VenR compared to 62.2% for BR. In the CLL14 trial, uMRD levels indicated better PFS outcomes. These results highlight VENCLEXTA's potential to improve patient outcomes significantly.
AbbVie (NYSE: ABBV) presented new data from the Phase 2 CAPTIVATE trial at the 2020 ASH Annual Meeting, showcasing the efficacy of IMBRUVICA® (ibrutinib) combined with VENCLEXTA®/VENCLYXTO® (venetoclax) for treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The results indicated a one-year disease-free survival (DFS) rate of 100% for patients receiving ibrutinib compared to 95.3% for placebo. This combination also demonstrated high rates of undetectable minimal residual disease (uMRD). The study's findings support a potential fixed-duration treatment option for CLL/SLL patients.
AbbVie and Frontier Medicines announced a strategic collaboration to discover and develop innovative small molecule therapeutics targeting challenging protein targets in oncology and immunology. AbbVie will provide an upfront payment of $55 million and cover R&D costs during pre-clinical development phases. The collaboration has the potential for milestone payments exceeding $1 billion and expanded target options. AbbVie aims to enhance its efforts in targeted protein degradation while Frontier retains rights to its internal programs.
AbbVie (NYSE: ABBV) and Frontier Medicines have entered a strategic collaboration aimed at discovering and commercializing small molecule therapeutics targeting challenging protein targets, especially in oncology and immunology.
AbbVie will provide an upfront payment of $55 million and cover Frontier's R&D costs through early development phases. Frontier can receive additional milestone payments, potentially exceeding $1 billion, as well as royalties on commercialized products. This partnership enhances AbbVie's focus on innovative drug development, particularly in protein degradation.
AbbVie will conduct a virtual immunology strategic update for investors on December 14, 2020, at 9:00 a.m. Central time. Richard A. Gonzalez, CEO, alongside the executive leadership team, will discuss AbbVie's immunology business and pipeline. Investors can access a live audio webcast on AbbVie's Investor Relations site, with an archived version available later that day. AbbVie's mission focuses on developing innovative medicines across various therapeutic areas, including immunology, oncology, and more.
AbbVie (NYSE: ABBV) will participate in the Evercore ISI Virtual HealthCONx Conference on December 2, 2020, at 1:40 p.m. CT, and the Piper Sandler Virtual Healthcare Conference on December 3, 2020, at 10 a.m. CT. Key executives, including Michael Severino, M.D., and Robert A. Michael, will present at both venues. Investors can access a live audio webcast from AbbVie's Investor Relations website, with archived versions available later that day. AbbVie's mission focuses on delivering innovative medicines across various therapeutic areas.
AbbVie announced the expiration and results of its Registered Exchange Offers for its outstanding senior unsecured notes totaling $30 billion and €2.5 billion. The offers concluded on November 17, 2020, with an impressive participation rate across multiple notes, notably a 100% exchange of the Senior Floating Rate Notes due November 2021. The company is set to settle the exchanges on November 19, 2020. The new Registered Notes will have similar terms to the Original Notes but will be registered under the Securities Act, eliminating certain transfer restrictions.